Rhelion Life Sciences Corp. (FRA:4YX0)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.49M -6.6% |
| Revenue (ttm) | 2.61M -15.1% |
| Net Income | -3.79M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0030 |
| Previous Close | 0.0030 |
| Day's Range | 0.0030 - 0.0095 |
| 52-Week Range | 0.0005 - 0.0300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Rhelion Life Sciences
Rhelion Life Sciences Corp. engages in the research and development of psychedelic drug in Netherlands, Canada, and the United States. Its products also include PEX010, a natural psilocybin drug candidate. It also engages in the production, growth, and sale of functional mushrooms and mushroom home grow kits to the recreational market in North America and Europe, as well as selection, distribution, and export of truffles. The company was formerly known as Red Light Holland Corp. and changed its name to Rhelion Life Sciences Corp. in August 2026... [Read more]
Financial Performance
In fiscal year 2026, Rhelion Life Sciences's revenue was 4.20 million, a decrease of -15.15% compared to the previous year's 4.94 million. Losses were -6.10 million, 51.0% more than in 2025.
Financial numbers in CAD Financial StatementsNews
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in pe...
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic m...
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovatio...
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment...
Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (OTCQB: TRUFF) (FSE: 4YX) ("Rhelion" or the "Company") is pleased to announce that it has completed its co...
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing innov...
Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
Rhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and innovation Toronto, Ont...
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization...
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1...
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization ...
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (F...
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France
Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization ...
Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers
Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF tr...
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported b...
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation a...
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwh...
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation an...
Red Light Holland Announces Intention to Rebrand
New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments Name change resolution to be voted on by shareholders at the u...
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, includ...
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") a...
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to ann...
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execu...
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, dep...
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and Canada Toronto, Ontario--(Newsfile Corp. - April 7, ...